New drug combination delayed disease progression for subgroup of women with metastatic breast cancer
Adding the drug dasatinib to a standard antihormone therapy, letrozole, doubled the time before disease progressed for women with hormone receptor-positive, HER2-negative metastatic breast cancer, according to results of ...
Dec 12, 2013
0
0